Barclays
DNLI icon

Barclays’s Denali Therapeutics DNLI Stock Holding History

Barclays’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-22,500
Closed -$483K – 5144
2023
Q4 		$483K Buy
+22,500
New +$446K ﹤0.01% 3897

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays's DNLI Position: Q1 2026 in Review

Barclays reduced its Denali Therapeutics (DNLI) stake by 87% in Q1 2026, selling an estimated $7.07M and leaving 52,084 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #2764.

Barclays first reported a position in DNLI in Q1 2018 and has held it in 32 quarters since. The position peaked at $16.3M in Q4 2022. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Barclays held 52,084 shares of Denali Therapeutics worth $1M as of Q1 2026.
  • Barclays sold 355,275 Denali Therapeutics shares in Q1 2026, an estimated $7.07M.
  • Denali Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2764 holding.
  • Barclays first reported a position in Denali Therapeutics in Q1 2018 and has held it in 32 quarters since.
  • Barclays's Denali Therapeutics position peaked at $16.3M in Q4 2022.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.